Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neratinib in advanced HER2+ breast cancer
NCT00300781Phase 2Completed
- Sponsor
- Puma Biotechnology, Inc.
- Start
- Aug 2006
- Primary completion
- Apr 2008
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 7
01
Overview
Phase 2, open-label trial of neratinib in breast cancer (2 arms), sponsored by Puma Biotechnology, Inc. Primary endpoint: Progression Free Survival at 16 weeks. Started Aug 2006; status: completed.
02
Drugs
neratinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00300781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00300781.